Primary central nervous system lymphoma in the elderly: a multicentre retrospective analysis

Elderly patients with primary central nervous ystem lymphoma (PCNSL) do not tolerate treatment with combined radio‐chemotherapy well because of leuco‐encephalopathy; they are usually treated initially with chemotherapy or radiotherapy alone. Little is known about the efficacy and toxicity of these treatments outside clinical studies. This study was a retrospective analysis of all patients aged 60 years or over who were admitted with PCNSL to one of five Dutch centers between 1998 and 2007. A total of 74 patients were identified. Twenty‐nine were treated with radiotherapy only (Group A), in 36 the intended treatment was chemotherapy alone (Group B), and nine were planned to receive chemotherapy followed by radiotherapy (Group C). Median overall survival was 20 months; 4 months in patients with a Karnofsky performance status (KPS) <70, 25 months in patients with a KPS ≥ 70 (P < 0·001). Treatment modality was not an independent prognostic factor. Forty patients were treated with methotrexate 3 g/m2: there were two toxic deaths. Ten patients discontinued chemotherapy because of toxicity. Delayed encephalopathy was reported in 10 patients. In conclusion, community hospitals still frequently utilize whole brain radiotherapy in elderly PCNSL patients, though a majority tolerates chemotherapy well. Performance status was the most important variable determining prognosis. Short and long term toxicities must be weighed against possible clinical benefits of each treatment, making treatment decisions a highly individualized process.

[1]  F. Feuerhake,et al.  High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  Jon D Wilson,et al.  Primary central nervous system lymphoma. , 2008, Archives of pathology & laboratory medicine.

[3]  L. Deangelis,et al.  Primary central nervous system lymphoma: The role of consolidation treatment after a complete response to high‐dose methotrexate‐based chemotherapy , 2008, Cancer.

[4]  K. Hoang-Xuan,et al.  Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly , 2007, Journal of Neuro-Oncology.

[5]  E. Elkin,et al.  Patterns of treatment in older adults with primary central nervous system lymphoma , 2007, Cancer.

[6]  L. Deangelis,et al.  Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma , 2007, Neurology.

[7]  K. Hoang-Xuan,et al.  Primary central nervous system lymphoma: biological aspects and controversies in management. , 2007, European journal of cancer.

[8]  D. Nelson,et al.  Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  B. O'neill,et al.  Whole-brain radiotherapy and high-dose methylprednisolone for elderly patients with primary central nervous system lymphoma: Results of North Central Cancer Treatment Group (NCCTG) 96-73-51. , 2004, International journal of radiation oncology, biology, physics.

[10]  D. Correa,et al.  Delayed neurotoxicity in primary central nervous system lymphoma. , 2005, Archives of neurology.

[11]  Y. Shibamoto,et al.  Results of radiation monotherapy for primary central nervous system lymphoma in the 1990s. , 2005, International journal of radiation oncology, biology, physics.

[12]  D. Finkelstein,et al.  Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  E. Thiel,et al.  High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  M. Taphoorn,et al.  White Matter Lesions and Encephalopathy in Patients Treated For Primary Central Nervous System Lymphoma , 2001, Journal of Neuro-Oncology.

[15]  R. Fimmers,et al.  Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M. van Glabbeke,et al.  High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  K. Hoang-Xuan,et al.  Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  J. Blay,et al.  Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  L. Deangelis,et al.  Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. Rosenthal,et al.  High-dose methotrexate for primary CNS lymphoma in the elderly. , 2000, Neuro-oncology.

[21]  J. Blay,et al.  High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  D. Nelson,et al.  Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. , 1992, International journal of radiation oncology, biology, physics.